Hemoglobinopathy: Difference between revisions
Line 43: | Line 43: | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | |,|-|-|-|-|+|-|.|}} | {{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | |,|-|-|-|-|+|-|.|}} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | H01 | | H02 | | H03| | |H01=[[Thalassemia|δβ-thalassemia]] |H02=εγδβ-[[Thalassemia|thalassemia]] |H03=[[Hereditary persistence of fetal hemoglobin|HPFH]] }} | {{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | H01 | | H02 | | H03| | |H01=[[Thalassemia|δβ-thalassemia]] |H02=εγδβ-[[Thalassemia|thalassemia]] |H03=[[Hereditary persistence of fetal hemoglobin|HPFH]] }} | ||
{{familytree/end}} | {{familytree/end}}</small> | ||
</small> | |||
The range of clinical manifestations of the hemoglobinopathies are from mild [[hypochromic anemia]] to moderate [[hematological disease]] to severe. | The range of clinical manifestations of the hemoglobinopathies are from mild [[hypochromic anemia]] to moderate [[hematological disease]] to severe. | ||
Line 50: | Line 49: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Prevalence=== | ===Prevalence=== | ||
*In 2008, the prevalence of hemoglobinopathy was estimated to be 7% | *In 2008, the prevalence of hemoglobinopathy carrier was estimated to be 700 per 100,000 (7%), worldwide.<ref name="pmid21886666">{{cite journal |vauthors=Kohne E |title=Hemoglobinopathies: clinical manifestations, diagnosis, and treatment |journal=Dtsch Arztebl Int |volume=108 |issue=31-32 |pages=532–40 |date=August 2011 |pmid=21886666 |pmc=3163784 |doi=10.3238/arztebl.2011.0532 |url=}}</ref> | ||
*The most | *The most prevalence of hemoglobinopathy gene carriers in the world's are in South-East Asia (up to 70%) and Arab nations (up to 60%).<ref name="pmid21886666" /> | ||
*In Russia is | *In Russia, prevalence of hemoglobinopathies is rare.<ref name="pmid21886666" /> | ||
* | *In recent years, prevale of hempglobinopathies is increased in Germany.<ref name="pmid10663615">{{cite journal |vauthors=Cario H, Stahnke K, Sander S, Kohne E |title=Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study |journal=Ann. Hematol. |volume=79 |issue=1 |pages=7–12 |date=January 2000 |pmid=10663615 |doi= |url=}}</ref> | ||
=== | ===Region=== | ||
'''α-thalassemias''' | '''α-thalassemias''' | ||
It | It occurs frequently in Africa, Arab nations, South-East Asia.<ref name="pmid218866662">{{cite journal |vauthors=Kohne E |title=Hemoglobinopathies: clinical manifestations, diagnosis, and treatment |journal=Dtsch Arztebl Int |volume=108 |issue=31-32 |pages=532–40 |date=August 2011 |pmid=21886666 |pmc=3163784 |doi=10.3238/arztebl.2011.0532 |url=}}</ref> | ||
'''β-thalassemias''' | '''β-thalassemias''' | ||
It | It occurs frequently in Mediterranean countries, South-East Europe, Arab nations, and Asia.<ref name="pmid218866663">{{cite journal |vauthors=Kohne E |title=Hemoglobinopathies: clinical manifestations, diagnosis, and treatment |journal=Dtsch Arztebl Int |volume=108 |issue=31-32 |pages=532–40 |date=August 2011 |pmid=21886666 |pmc=3163784 |doi=10.3238/arztebl.2011.0532 |url=}}</ref> | ||
== Diagnosis == | == Diagnosis == | ||
Line 70: | Line 69: | ||
{{familytree | | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | A01=History & clinical [[Symptom|symptoms]] }} | {{familytree | | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | A01=History & clinical [[Symptom|symptoms]] }} | ||
{{familytree | | | | | |,|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|.| | | | | | | | | }} | {{familytree | | | | | |,|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|.| | | | | | | | | }} | ||
{{familytree | | | | | B01 | | | | | | | | | | | | | | | | | | B02 | | | | | | | | |B01=[[Blood test|Blood test]] |B02= | {{familytree | | | | | B01 | | | | | | | | | | | | | | | | | | B02 | | | | | | | | |B01=[[Blood test|Blood test]] |B02=Hemolysate | | | }} | ||
{{familytree | | | | | | | | | | |,|-|-|-|-|-|-|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|-|.| | | | }} | {{familytree | | | | | | | | | | |,|-|-|-|-|-|-|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|-|.| | | | }} | ||
{{familytree | | | | | | | | | | | C01 | | | | | | | | | | | | C02 | | | | | | | | C03 | | |C01=[[Diagnosis|Diagnosis]] of abnormal [[Hemoglobin|hemoglobins]] |C02=[[Diagnosis|Diagnosis]] of [[Thalassemia|β-thalassemia]] |C03=[[Diagnosis|Diagnosis]] of [[Thalassemia|α-thalassemia]] | | | }} | {{familytree | | | | | | | | | | | C01 | | | | | | | | | | | | C02 | | | | | | | | C03 | | |C01=[[Diagnosis|Diagnosis]] of abnormal [[Hemoglobin|hemoglobins]] |C02=[[Diagnosis|Diagnosis]] of [[Thalassemia|β-thalassemia]] |C03=[[Diagnosis|Diagnosis]] of [[Thalassemia|α-thalassemia]] | | | }} | ||
{{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | | |!| | | |}} | {{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | | |!| | | |}} | ||
{{familytree | | | | | | | | | | | D01 | | | | | | | | | | | | D02 | | | | | | | | D03| | |D01=Alkaline [[Electrophoresis|electrophoresis]]<br>• [[Acid|acid]] [[Electrophoresis | {{familytree | | | | | | | | | | | D01 | | | | | | | | | | | | D02 | | | | | | | | D03| | |D01=Alkaline [[Electrophoresis|electrophoresis]]<br>• [[Acid|acid]] [[Electrophoresis]]<br>•[[High performance liquid chromatography|HPLC]] |D02=[[Electrophoresis|Electrophoresis]] [[High performance liquid chromatography|HPLC]]<br>• [[Hemoglobin|HbA2]],[[Hemoglobin|Hbf]] |D03=[[Electrophoresis]] [[High performance liquid chromatography|HPLC]]<br>• [[Genetic fingerprinting|DNA testing]] | | |}} | ||
{{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | | |!| | | |}} | {{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | | |!| | | |}} | ||
{{familytree | | | | | | | |,|-|-|-|^|-|-|.| | | | | | | | | | |!| | | | | | | | | |!| | | |}} | {{familytree | | | | | | | |,|-|-|-|^|-|-|.| | | | | | | | | | |!| | | | | | | | | |!| | | |}} | ||
Line 80: | Line 79: | ||
{{familytree | | | | | | | | |!| | | | |!| | | | | | | | | | | |!| | | | | | | | | |!| | }} | {{familytree | | | | | | | | |!| | | | |!| | | | | | | | | | | |!| | | | | | | | | |!| | }} | ||
{{familytree | | | | | | | | |`|-|v|-|-|'| | | | | | | | | | | |!| | | | | | | | | |!| | }} | {{familytree | | | | | | | | |`|-|v|-|-|'| | | | | | | | | | | |!| | | | | | | | | |!| | }} | ||
{{familytree | | | | | | | | | | |!| | | | | | | | | | | | | | F01 | | | | | | | | F02 | | |F01= | {{familytree | | | | | | | | | | |!| | | | | | | | | | | | | | F01 | | | | | | | | F02 | | |F01=Diagnosis of [[Thalassemia|β-thalassemia]] |F02=[[Diagnosis]] of [[Thalassemia|α-thalassemia]] | | |}} | ||
{{familytree | | | | | | | | | | |!| | | | | | | | | | | | | | |!| | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | |!| | | | | | | | | | | | | | |!| | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | G01 | | | | | | | | | | | | | G02 | | |G01=[[DNA sequencing|DNA sequencing]] if needed |G02=[[DNA sequencing|DNA sequencing]] if needed([[Thalassemia|thalassemia]] major, [[Thalassemia|thalassemia]] intermedia | | |}} | {{familytree | | | | | | | | | | G01 | | | | | | | | | | | | | G02 | | |G01=[[DNA sequencing|DNA sequencing]] if needed |G02=[[DNA sequencing|DNA sequencing]] if needed([[Thalassemia|thalassemia]] major, [[Thalassemia|thalassemia]] intermedia | | |}} |
Revision as of 15:08, 13 September 2018
Hemoglobinopathy Main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Hemoglobinopathy is a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule. Most common hemoglobinopathies include sickle-cell disease.The renge of clinical manifestations of the hemoglobinopathies are from mild hypochromic anemia to moderate hematological disease to severe.
Classification
Hemoglobinopathy be classified according to genetic and structure of hemoglobin into two main groups:[1]
The range of clinical manifestations of the hemoglobinopathies are from mild hypochromic anemia to moderate hematological disease to severe.
Epidemiology and Demographics
Prevalence
- In 2008, the prevalence of hemoglobinopathy carrier was estimated to be 700 per 100,000 (7%), worldwide.[2]
- The most prevalence of hemoglobinopathy gene carriers in the world's are in South-East Asia (up to 70%) and Arab nations (up to 60%).[2]
- In Russia, prevalence of hemoglobinopathies is rare.[2]
- In recent years, prevale of hempglobinopathies is increased in Germany.[3]
Region
α-thalassemias
It occurs frequently in Africa, Arab nations, South-East Asia.[4]
β-thalassemias
It occurs frequently in Mediterranean countries, South-East Europe, Arab nations, and Asia.[5]
Diagnosis
Hemoglobin testing(hemoglobin electrophoresis or chromatography) , [[Red blood cell
|red blood cell]] count, hemoglobin pattern, cardinal symptoms[6]
History & clinical symptoms | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Blood test | Hemolysate | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of abnormal hemoglobins | Diagnosis of β-thalassemia | Diagnosis of α-thalassemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alkaline electrophoresis • acid Electrophoresis •HPLC | Electrophoresis HPLC • HbA2,Hbf | Electrophoresis HPLC • DNA testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evidence of abnormality,comparison of mobility with that of known abnormalities, if HBS suspected: solubility test | Separation/quantification | Evalution of all data and findings | Evalution of all data and findings | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of β-thalassemia | Diagnosis of α-thalassemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DNA sequencing if needed | DNA sequencing if needed(thalassemia major, thalassemia intermedia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evaluation of all data and findings(including blood count ethnic and origin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of hemoglobinopathy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ Forget BG, Bunn HF (February 2013). "Classification of the disorders of hemoglobin". Cold Spring Harb Perspect Med. 3 (2): a011684. doi:10.1101/cshperspect.a011684. PMC 3552344. PMID 23378597.
- ↑ 2.0 2.1 2.2 Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
- ↑ Cario H, Stahnke K, Sander S, Kohne E (January 2000). "Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study". Ann. Hematol. 79 (1): 7–12. PMID 10663615.
- ↑ Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
- ↑ Kohne E (August 2011). "Hemoglobinopathies: clinical manifestations, diagnosis, and treatment". Dtsch Arztebl Int. 108 (31–32): 532–40. doi:10.3238/arztebl.2011.0532. PMC 3163784. PMID 21886666.
- ↑ Herklotz R, Risch L, Huber AR (January 2006). "[Hemoglobinopathies--clinical symptoms and diagnosis of thalassemia and abnormal hemoglobins]". Ther Umsch (in German). 63 (1): 35–46. doi:10.1024/0040-5930.63.1.35. PMID 16450733.